Press release MHRA approves GLP –one receptor agonist semaglutide to scale back possibility of significant coronary heart complications in obese or overweight adults Semaglutide is the initial weight reduction drug accredited in the united kingdom for a preventative cure for anyone with established cardiovascular diseaseThere are a number of smal